Literature DB >> 23485365

A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.

David M Feliciano1, Tiffany V Lin, Nathaniel W Hartman, Christopher M Bartley, Cathryn Kubera, Lawrence Hsieh, Carlos Lafourcade, Rachel A O'Keefe, Angelique Bordey.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant monogenetic disorder that is characterized by the formation of benign tumors in several organs as well as brain malformations and neuronal defects. TSC is caused by inactivating mutations in one of two genes, TSC1 and TSC2, resulting in increased activity of the mammalian Target of Rapamycin (mTOR). Here, we explore the cytoarchitectural and functional CNS aberrations that may account for the neurological presentations of TSC, notably seizures, hydrocephalus, and cognitive and psychological impairments. In particular, recent mouse models of brain lesions are presented with an emphasis on using electroporation to allow the generation of discrete lesions resulting from loss of heterozygosity during perinatal development. Cortical lesions are thought to contribute to epileptogenesis and worsening of cognitive defects. However, it has recently been suggested that being born with a mutant allele without loss of heterozygosity and associated cortical lesions is sufficient to generate cognitive and neuropsychiatric problems. We will thus discuss the function of mTOR hyperactivity on neuronal circuit formation and the potential consequences of being born heterozygous on neuronal function and the biochemistry of synaptic plasticity, the cellular substrate of learning and memory. Ultimately, a major goal of TSC research is to identify the cellular and molecular mechanisms downstream of mTOR underlying the neurological manifestations observed in TSC patients and identify novel therapeutic targets to prevent the formation of brain lesions and restore neuronal function.
Copyright © 2013 ISDN. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4E-BP1; Autism; CNS; CSF; CreERT2; Dendrite; Differentiation; E; EEG; Epilepsy; FCDs; FMR1; FMRP; FMRP gene; FXS; GAP; GFAP; GTPase activating protein; IUE; LOH; LTD; LTP; LV; MRI; Mental retardation; Migration; Neurogenesis; P; PP2A; Progenitor cell; RGCs; Ras homolog enriched in brain; Rheb; S6K1; SEGA; SEN; SEZ; Seizures; Spine; Stem cell; SynI-Cre; Synapsin I promoter-driven Cre; TSC; TSC gene 1 or gene 2; TSC1 or TSC2; Tsc1(fl/fl); Tsc1(fl/mut); Tsc1(wt/mut); Tuber; Tuberous sclerosis complex; central nervous system; cerebral spinal fluid; eIF4E-binding protein 1; electroencephalography; embryonic day; fl; floxed; floxed Tsc1 alleles (transgenic mice); floxed and mutant Tsc1 alleles; focal cortical dysplasias; fragile X mental retardation protein; fragile X syndrome; glial fibrillary acidic protein; hgfap; human gfap; in utero electroporation; inducible Cre; lateral ventricle; long-term depression; long-term potentiation; loss of heterozygosity; mGluR-LTD; mTOR; mTOR complex 1 or 2; mTORC1 or mTORC2; magnetic resonance imaging; mammalian Target of Rapamycin; metabotropic glutamate receptor class I long term depression; mgfap; mouse gfap; p70 S6 Kinase 1; postnatal day; protein phosphatase 2A; retinal ganglion cells; subependymal giant cell astrocytoma; subependymal nodules; subependymal zone; tuberous sclerosis complex; wildtype and mutant Tsc1 alleles

Mesh:

Substances:

Year:  2013        PMID: 23485365      PMCID: PMC3830611          DOI: 10.1016/j.ijdevneu.2013.02.008

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  165 in total

1.  Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons.

Authors:  Malgorzata Urbanska; Agata Gozdz; Lukasz J Swiech; Jacek Jaworski
Journal:  J Biol Chem       Date:  2012-07-18       Impact factor: 5.157

2.  Subependymal giant cell astrocytoma: clinical, histologic and immunohistochemical characteristic of 3 cases.

Authors:  A Taraszewska; H Kroh; A Majchrowski
Journal:  Folia Neuropathol       Date:  1997       Impact factor: 2.038

3.  Germ-line mosaicism in tuberous sclerosis: how common?

Authors:  V M Rose; K S Au; G Pollom; E S Roach; H R Prashner; H Northrup
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

4.  Diffusion features of white matter in tuberous sclerosis with tractography.

Authors:  Michelle L Krishnan; Olivier Commowick; Shafali S Jeste; Neil Weisenfeld; Arne Hans; Matthew C Gregas; Mustafa Sahin; Simon K Warfield
Journal:  Pediatr Neurol       Date:  2010-02       Impact factor: 3.372

5.  Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the ΔRG mouse model of tuberous sclerosis complex.

Authors:  Itzamarie Chévere-Torres; Hanoch Kaphzan; Aditi Bhattacharya; Areum Kang; Jordan M Maki; Michael J Gambello; Jack L Arbiser; Emanuela Santini; Eric Klann
Journal:  Neurobiol Dis       Date:  2011-12-16       Impact factor: 5.996

6.  Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features.

Authors:  Elizabeth Yuan; Peter T Tsai; Emily Greene-Colozzi; Mustafa Sahin; David J Kwiatkowski; Izabela A Malinowska
Journal:  Hum Mol Genet       Date:  2012-06-29       Impact factor: 6.150

Review 7.  PTEN signaling in brain: neuropathology and tumorigenesis.

Authors:  R Endersby; S J Baker
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

8.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

9.  The molecular genetics of tuberous sclerosis.

Authors:  J R Sampson; P C Harris
Journal:  Hum Mol Genet       Date:  1994       Impact factor: 6.150

10.  Olfactory hamartomas in tuberous sclerosis.

Authors:  G A de León; N Zaeri; C M Foley
Journal:  J Neurol Sci       Date:  1988-11       Impact factor: 3.181

View more
  32 in total

1.  More Than mTOR? Novel Roles for MEK-ERK1/2 and FLNA in Tuberous Sclerosis Complex.

Authors:  Chris G Dulla
Journal:  Epilepsy Curr       Date:  2015 Jul-Aug       Impact factor: 7.500

Review 2.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

3.  Hypoxia-inducible factor-1a contributes to dendritic overgrowth in tuberous sclerosis.

Authors:  Longbo Zhang; David M Feliciano; Tianxiang Huang; Shiliang Zhang; Angélique Bordey
Journal:  Neurosci Lett       Date:  2015-12-02       Impact factor: 3.046

4.  Neurosurgical treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex: a series of 44 surgical procedures in 31 patients.

Authors:  Flavio Giordano; Carla Moscheo; Matteo Lenge; Roberto Biagiotti; Francesco Mari; Iacopo Sardi; Anna Maria Buccoliero; Lorenzo Mongardi; Eleonora Aronica; Renzo Guerrini; Lorenzo Genitori
Journal:  Childs Nerv Syst       Date:  2019-12-18       Impact factor: 1.475

5.  FoxO Function Is Essential for Maintenance of Autophagic Flux and Neuronal Morphogenesis in Adult Neurogenesis.

Authors:  Iris Schäffner; Georgia Minakaki; M Amir Khan; Elli-Anna Balta; Ursula Schlötzer-Schrehardt; Tobias J Schwarz; Ruth Beckervordersandforth; Beate Winner; Ashley E Webb; Ronald A DePinho; Jihye Paik; Wolfgang Wurst; Jochen Klucken; D Chichung Lie
Journal:  Neuron       Date:  2018-09-06       Impact factor: 17.173

6.  Hypervascularization in mTOR-dependent focal and global cortical malformations displays differential rapamycin sensitivity.

Authors:  Longbo Zhang; Tianxiang Huang; Shannon Teaw; Angélique Bordey
Journal:  Epilepsia       Date:  2019-05-24       Impact factor: 5.864

7.  MEK-ERK1/2-dependent FLNA overexpression promotes abnormal dendritic patterning in tuberous sclerosis independent of mTOR.

Authors:  Longbo Zhang; Christopher M Bartley; Xuan Gong; Lawrence S Hsieh; Tiffany V Lin; David M Feliciano; Angélique Bordey
Journal:  Neuron       Date:  2014-10-01       Impact factor: 17.173

8.  mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.

Authors:  Lena H Nguyen; Travorn Mahadeo; Angélique Bordey
Journal:  J Neurosci       Date:  2019-01-30       Impact factor: 6.167

9.  Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.

Authors:  Avery J Zucco; Valentina Dal Pozzo; Alina Afinogenova; Ronald P Hart; Orrin Devinsky; Gabriella D'Arcangelo
Journal:  Mol Cell Neurosci       Date:  2018-08-23       Impact factor: 4.314

10.  Tsc1 haploinsufficiency is sufficient to increase dendritic patterning and Filamin A levels.

Authors:  Longbo Zhang; Tianxiang Huang; Angélique Bordey
Journal:  Neurosci Lett       Date:  2016-06-21       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.